Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s preclinical drug for inflammatory diseases in a deal that comes almost two decades after Novartis’ first pact with the Japanese drugmaker. The Swiss company ...